BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

850 related articles for article (PubMed ID: 3604540)

  • 21. The use of cytology to evaluate pericardial effusions.
    King DT; Nieberg RK
    Ann Clin Lab Sci; 1979; 9(1):18-23. PubMed ID: 420509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cytologic application of carcinoembryonic antigen for the discrimination of malignant from benign serous effusions.
    Kyrkou KA; Iatridis SG; Athanassiadou PP; Athanassiadis PP; Mandragos CE
    Cancer Detect Prev; 1985; 8(1-2):247-54. PubMed ID: 4064045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An immunoperoxidase study of S-100 protein in neoplastic cells in serous effusions. Use as a marker for melanoma.
    Pinto MM
    Acta Cytol; 1986; 30(3):240-4. PubMed ID: 3521174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.
    Lee BH; Hecht JL; Pinkus JL; Pinkus GS
    Am J Clin Pathol; 2002 May; 117(5):745-50. PubMed ID: 12090423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cytological variations observed in the malignant cells in body cavity fluids].
    Matsuda M
    Rinsho Byori; 1990 Nov; Suppl 87():69-85. PubMed ID: 2287091
    [No Abstract]   [Full Text] [Related]  

  • 26. Application of molecular genetics to the diagnosis of lymphoid-rich effusions: study of 95 cases with concomitant immunophenotyping.
    Mihaescu A; Gebhard S; Chaubert P; Rochat MC; Braunschweig R; Bosman FT; Delacrétaz F; Benhattar J
    Diagn Cytopathol; 2002 Aug; 27(2):90-5. PubMed ID: 12203875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignancies in Pleural, Peritoneal, and Pericardial Effusions.
    Dermawan JKT; Policarpio-Nicolas ML
    Arch Pathol Lab Med; 2020 Sep; 144(9):1086-1091. PubMed ID: 31913661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.
    Yeo KT; Wang HH; Nagy JA; Sioussat TM; Ledbetter SR; Hoogewerf AJ; Zhou Y; Masse EM; Senger DR; Dvorak HF
    Cancer Res; 1993 Jun; 53(12):2912-8. PubMed ID: 8504432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
    Illei PB; Ladanyi M; Rusch VW; Zakowski MF
    Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of an antibody to human milk fat globule antigen in the detection of metastatic carcinoma in pleural, pericardial and peritoneal fluids.
    Hilborne LH; Cheng L; Nieberg RK; Lewin KJ
    Acta Cytol; 1986; 30(3):245-50. PubMed ID: 2424206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of immunohistochemistry staining and cytologic diagnosis by using cell block sections prepared with effusion fluid cytology specimens].
    Mao YY; Yang M; Liu DG; Lin MH; Zhang LQ; Chen ZQ
    Zhonghua Bing Li Xue Za Zhi; 2009 Aug; 38(8):547-50. PubMed ID: 20021967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
    Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
    Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis and categorization of malignant effusions: A 6-year review from a single academic institution.
    Lew M; Cantley R; Heider A; Jing X
    Diagn Cytopathol; 2021 May; 49(5):615-621. PubMed ID: 32275354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Preparatory techniques of fluids and screening of malignant cells in effusions].
    Nagumo S
    Rinsho Byori; 1990 Nov; Suppl 87():191-200. PubMed ID: 2287088
    [No Abstract]   [Full Text] [Related]  

  • 35. Transforming growth factor activity in pleural and peritoneal effusions from cancer and non-cancer patients.
    Sairenji M; Suzuki K; Murakami K; Motohashi H; Okamoto T; Umeda M
    Jpn J Cancer Res; 1987 Aug; 78(8):814-8. PubMed ID: 3115927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study of effusion cytology in patients with simultaneous malignancy and ascites.
    Jha R; Shrestha HG; Sayami G; Pradhan SB
    Kathmandu Univ Med J (KUMJ); 2006; 4(4):483-7. PubMed ID: 18603959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
    Ciampa A; Fanger G; Khan A; Rock KL; Xu B
    Cancer; 2004 Dec; 102(6):368-72. PubMed ID: 15558786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology.
    Granados R; Cibas ES; Fletcher JA
    Acta Cytol; 1994; 38(5):711-7. PubMed ID: 8091903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pericellular lacunae in the diagnosis of metastatic carcinoma in effusions: is this a useful sign?
    Thomson T; Hayes MM
    Diagn Cytopathol; 1996 Sep; 15(3):193-6. PubMed ID: 8955600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Carcinoembryonic antigen in ascites and pleural effusions].
    Lirzin P; Zeitoun P; Vandromme L; Salas H
    Gastroenterol Clin Biol; 1984 Mar; 8(3):222-7. PubMed ID: 6714557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.